Cancer and Hematology Centers Of Western Michigan | CHCWM East - Grand Rapids, MI

Research site

(Unclaimed)

Location

5800 Foremost Drive, Grand Rapids, Michigan, United States of America

Site insights

Top conditions

Top treatments

Pembrolizumab

Nivolumab

Cyclophosphamide

Vincristine

Doxorubicin

Atezolizumab

Irinotecan

Prednisone

LY3537982

Durvalumab

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

17 of 34 total trials

A Clinical Study of V940 Plus Pembrolizumab in People With High-Risk Melanoma (V940-001)

The purpose of this study is to learn if V940 which is an individualized neoantigen therapy (INT; formerly, called messenger ribonucleic acid \[mRNA\...

Enrolling

Melanoma

Biological: Pembrolizumab

Biological: V940

A Phase 3 Study of Pacritinib in Patients With Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis (PACIFICA)

This study (study ID PAC203 North America; PAC303 ex-North America) is evaluating 200 mg BID of pacritinib compared to physician's choice (P/C) thera...

Enrolling

Post-essential Thrombocythemia Myelofibrosis

Post-polycythemia Vera Myelofibrosis

Drug: Physician's Choice medications

Drug: Pacritinib

A Study of LY3537982 Plus Immunotherapy With or Without Chemotherapy in Participants With Non-Small Cell Lung Cancer (NSCLC) With a Change in a Gene Called KRAS G12C (SUNRAY-01)

The purpose of this study is to assess if adding LY3537982 in combination with standard of care anti-cancer drugs is more effective than standard of...

Enrolling

Carcinoma, Non-Small-Cell Lung

Neoplasm Metastasis

Drug: Carboplatin

Drug: LY3537982

A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)

The purpose of this study is to assess the efficacy and safety of opevesostat plus hormone replacement therapy (HRT) compared to alternative abirater...

Enrolling

Metastatic Castration-resistant Prostate Cancer (mCRPC)

Prostatic Neoplasms

Drug: Enzalutamide

Drug: Dexamethasone

A Study to Assess the Effectiveness and Safety of Irinotecan Liposome Injection, 5-fluorouracil/Leucovorin Plus Oxaliplatin in Patients Not Previously Treated for Metastatic Pancreatic Cancer, Compared to Nab-paclitaxel+Gemcitabine Treatment (NAPOLI 3)

The purpose of this study is to look at the efficacy and safety of Irinotecan liposome injection in combination with other approved drugs used for ca...

Active, not recruiting

Metastatic Adenocarcinoma of the Pancreas

Drug: Leucovorin

Drug: Gemcitabine

Locations recently updated

A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Patients With Previously Untreated Diffuse Large B-cell Lymphoma (OLYMPIA-3)

This study is researching an experimental drug called odronextamab, referred to as study drug, when used in combination with chemotherapy. The study...

Enrolling

Diffuse Large B-cell Lymphoma (DLBCL)

Drug: Doxorubicin

Drug: Prednisone/Prednisolone

A Trial to Learn if Odronextamab Combined With Chemotherapy is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Chemotherapy for Adult Participants With Follicular Lymphoma (OLYMPIA-2)

This study is researching an experimental drug called odronextamab, referred to as study drug. The study is focused on participants with previously u...

Enrolling

Follicular Lymphoma (FL)

Drug: Odronextamab

Drug: Vincristine

Efficacy and Safety of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) Plus Chemotherapy in Participants With Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-7902-015/E7080-G000-321/LEAP-015)

The purpose of this study is to assess the efficacy and safety of lenvatinib (E7080/MK-7902) plus pembrolizumab (MK-3475) plus chemotherapy compared...

Active, not recruiting

Advanced/Metastatic Gastroesophageal Adenocarcinoma

Drug: 5-FU

Biological: Lenvatinib

Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation (ELAINEIII)

The goal of this clinical trial is to assess the efficacy, safety and tolerability of the combination of lasofoxifene and abemaciclib compared to ful...

Enrolling

Metastatic Breast Cancer

Drug: Lasofoxifene in combination with abemaciclib

Drug: Fulvestrant in combination with abemaciclib

Ifinatamab Deruxtecan (I-DXd) in Subjects With Pretreated Extensive-Stage Small Cell Lung Cancer (ES-SCLC) (IDeate-Lung01)

This 2-part study intends to define the recommended Phase 2 dose of ifinatamab deruxtecan (I-DXd) based on the efficacy, safety, and pharmacokinetics...

Active, not recruiting

Extensive-stage Small-cell Lung Cancer

Drug: Ifinatamab Deruxtecan (I-DXd)

Pembrolizumab/Vibostolimab (MK-7684A) or Atezolizumab in Combination With Chemotherapy in First Line Treatment of Extensive-Stage Small Cell Lung Cancer (MK-7684A-008, KEYVIBE-008)

This study will evaluate the combination of a fixed dose pembrolizumab/vibostolimab co-formulation (MK-7684A) with etoposide/platinum chemotherapy fo...

Active, not recruiting

Small Cell Lung Carcinoma

Drug: Saline placebo

Biological: Atezolizumab

Phase Ib/II Trial of Nal-Irinotecan and Nivolumab as Second-Line Treatment in Patients With Advanced Biliary Tract Cancer

The purpose of this study is to test the effectiveness (how well the drug works), safety, and tolerability of the investigational drug combination of...

Active, not recruiting

Biliary Tract Cancer

Drug: Leucovorin

Drug: Nanoliposomal-Irinotecan

Locations recently updated

Study Comparing Tarlatamab and Durvalumab Versus Durvalumab Alone in First-Line Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) Following Platinum, Etoposide and Durvalumab (DeLLphi-305)

The primary objective of this study is to compare the efficacy of tarlatamab plus durvalumab with durvalumab alone on prolonging overall survival (OS...

Enrolling

Small-Cell Lung Cancer

Extensive-Stage Small-Cell Lung Cancer

Drug: Tarlatamab

Drug: Durvalumab

Study of Pembrolizumab/Vibostolimab Coformulation (MK-7684A) in Combination With Chemotherapy Versus Pembrolizumab Plus Chemotherapy in Participants With Metastatic Non-Small Cell Lung Cancer (MK-7684A-007/KEYVIBE-007)

The primary hypothesis is that pembrolizumab/vibostolimab (MK-7684A) in combination with chemotherapy is superior to pembrolizumab in combination wit...

Active, not recruiting

Metastatic Non-Small Cell Lung Cancer

Biological: Pembrolizumab

Drug: Cisplatin

Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/NSABP B-63)

The goal of this study is to find out if the experimental product, sacituzumab govitecan-hziy (SG) in combination with pembrolizumab given after surg...

Enrolling

Triple Negative Breast Cancer

Drug: Capecitabine

Drug: Sacituzumab govitecan-hziy (SG)

Study of the Safety, Tolerability and Efficacy of KPT-8602 in Participants With Relapsed/Refractory Cancer Indications

This is a first-in-human, multi-center, open-label clinical study with separate dose escalation (Phase 1) and expansion (Phase 2) stages to assess pr...

Active, not recruiting

Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Relapsed/Refractory Multiple Myeloma (RRMM)

Drug: ASTX727

Drug: KPT-8602

Study to Assess Safety and Efficacy of Atezolizumab (MPDL3280A) Compared to Best Supportive Care Following Chemotherapy in Patients With Lung Cancer [IMpower010]

This is a Phase III, global, multicenter, open-label, randomized study to compare the efficacy and safety of 16 cycles (1 cycle duration=21 days) of...

Active, not recruiting

Non-Small Cell Lung Cancer

Drug: Gemcitabine

Drug: Pemetrexed